CanSino Biologics to Announce 2024 Annual Results and Dividend Consideration

Story Highlights
CanSino Biologics to Announce 2024 Annual Results and Dividend Consideration

An update from CanSino Biologics, Inc. Class H ( (HK:6185) ) is now available.

CanSino Biologics Inc. has announced a board meeting scheduled for March 25, 2025, to discuss and approve the company’s annual results for the year ending December 31, 2024. The meeting will also consider the recommendation of a final dividend payment, reflecting the company’s financial performance and potential shareholder returns.

More about CanSino Biologics, Inc. Class H

CanSino Biologics Inc. is a biotechnology company based in China, specializing in the development and production of vaccines. The company is focused on providing innovative vaccine solutions to address public health challenges.

YTD Price Performance: 14.29%

Average Trading Volume: 1,234,804

Technical Sentiment Consensus Rating: Sell

Current Market Cap: HK$10.96B

See more data about 6185 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App